News & Events
In the news
How can customized solutions speed up successful GMP manufacturing?
The next edition of our webinar series will be centred on customised solutions when designing GMP processes to manufacture biologics and will take place on June, 23rd.
Discover our team:
Ysaline Roland, Production manager at Naobios
Our newest series of articles promote the people that make up our company and its human-centric values and objectives. Our latest profile is dedicated to Ysaline Roland, Production Manager at Naobios.
Naobios signs Service Agreement with Nobelpharma
Naobios will rely on its 15 years of expertise in process development and GMP manufacturing to support Nobelpharma develop its product. Naobios collaborated last year with the Japan-based company on preliminary studies.
Save the date !
Congresses 2022: meet our teams!
Teams at Naobios are traveling the world to attend major conferences and congresses within the biotech sector. As leaders of the biopharma field, our mission and our drive at the Clean Biologics group are to remain both reachable and up-to-date with regards to the latest developments and innovations.
Clean Mails – Revue scientifique trimestrielle
BSL3 GMP manufacturing suite – Naobios
Our team at Naobios has qualified a highly-secured BSL3 GMP manufacturing suite in our multipurpose facility to accommodate challenging GMP production projects involving viral vaccines, viral vectors and oncolytic viruses.
Are you choosing the right CDMO for your project?
This webinar will explore criteria to consider when selecting a new CDMO to undertake manufacturing of clinical biological substances. Il will take place on 25 November 2021 and will be led by the team at Naobios.
Meet our teams at CPHI Worldwide
Meet the teams from companies Clean Cells & Naobios next November as they attend CPHI Worldwide.
Naobios manufactures FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
Naobios’ development work and GMP manufacturing of vaccine clinical batches will enable FluGen to prepare its 2022 clinical trials in the United States.